Screener
Viking Therapeutics VKTX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Revenues | Three Months Ended March 31, 2026 / — | Three Months Ended March 31, 2025 / — |
|---|---|---|
| Research and development | 150,150 | 41,391 |
| General and administrative | 13,975 | 14,078 |
| Total operating expenses | 164,125 | 55,469 |
| Loss from operations | (164,125) | (55,469) |
| Other income (expense): | ||
| Amortization of financing costs | — | (24) |
| Interest income, net | 5,800 | 9,864 |
| Total other income, net | 5,800 | 9,840 |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's operating income?
- Viking Therapeutics (VKTX) reported operating income of -$164.13M in Q1 2026.
- How has Viking Therapeutics's operating income changed year-over-year?
- Viking Therapeutics's operating income decreased by 195.9% year-over-year, from -$55.47M to -$164.13M.
- What is the long-term trend for Viking Therapeutics's operating income?
- Over 4 years (2021 to 2025), Viking Therapeutics's operating income has grown at a 63.0% compound annual growth rate (CAGR), from -$55.68M to -$393.34M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Viking Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude